This document provides an overview of building proton therapy centers in China. It discusses the technology behind proton therapy and how it has overcome barriers to become commercially viable. The market potential in China is large, as cancer cases are growing rapidly and proton therapy can treat many of the most common cancer types. The projected market size is 150 proton therapy centers needed to meet demand. Currently China has two centers in operation and several more in development.
Concord Medical Services Holdings Ltd. is a leading provider of radiotherapy and diagnostic imaging services in China. It operates a nationwide network of 130 centers with 74 hospital partners in 24 provinces. The presentation highlights the company's strong growth, leading market position, and expansion strategies through network growth, new technology, and developing specialty cancer hospitals. Financial results show increasing revenue, profitability, and a solid capital structure to support continued growth.
Only a small percentage of cancer patients are good candidates for proton therapy. Yet, for the right patients, proton therapy can reduce radiation exposure to healthy tissue. To help you make the best care decisions, this slide deck offers information to help you identify those of cancer patients best treated with proton therapy.
Wavelength February 2012 Volume 16 No. 1Jerry Duncan
1) Elekta recently acquired Nucletron, the world leader in brachytherapy, consolidating its position as a complete provider of radiation oncology.
2) Brachytherapy involves placing a radiation source inside or next to the tumor, allowing high doses to be delivered over a short period while minimizing side effects.
3) Brachytherapy is often used in combination with other therapies like surgery and external beam radiation for cancers of the prostate, breast, gynecological organs, and is being studied for use in additional cancers and treatment combinations.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
This document discusses the opportunity for proton therapy in India to address the country's high cancer burden. It notes that India has over 5 million cancer patients annually with high mortality rates due to late-stage diagnoses. Proton therapy could benefit around 300,000 patients per year by precisely targeting tumors while sparing healthy tissue, especially for cancers near vital organs. The document calls for a workshop to develop a roadmap for establishing a Center of Excellence in India for proton therapy and advanced oncology technologies. The goal is to position India as a leader in cancer care through locally developed solutions.
Get the right cancer drug, at right TimeSubin Suresh
Mitra Biotech is a Boston and Bengaluru-based startup that is developing personalized cancer therapies. It focuses on testing drugs on recreated tumor microenvironments in the lab before human trials. This approach has higher success rates and lower toxicity than conventional trials. Mitra Biotech has raised over $27 million to develop these personalized therapies and diagnostics. Major challenges include high costs, ensuring data quality, and coordinating information between different treatment centers.
Concord Medical Services Holdings Ltd. is a leading provider of radiotherapy and diagnostic imaging services in China. It operates a nationwide network of 130 centers with 74 hospital partners in 24 provinces. The presentation highlights the company's strong growth, leading market position, and expansion strategies through network growth, new technology, and developing specialty cancer hospitals. Financial results show increasing revenue, profitability, and a solid capital structure to support continued growth.
Only a small percentage of cancer patients are good candidates for proton therapy. Yet, for the right patients, proton therapy can reduce radiation exposure to healthy tissue. To help you make the best care decisions, this slide deck offers information to help you identify those of cancer patients best treated with proton therapy.
Wavelength February 2012 Volume 16 No. 1Jerry Duncan
1) Elekta recently acquired Nucletron, the world leader in brachytherapy, consolidating its position as a complete provider of radiation oncology.
2) Brachytherapy involves placing a radiation source inside or next to the tumor, allowing high doses to be delivered over a short period while minimizing side effects.
3) Brachytherapy is often used in combination with other therapies like surgery and external beam radiation for cancers of the prostate, breast, gynecological organs, and is being studied for use in additional cancers and treatment combinations.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
This document discusses the opportunity for proton therapy in India to address the country's high cancer burden. It notes that India has over 5 million cancer patients annually with high mortality rates due to late-stage diagnoses. Proton therapy could benefit around 300,000 patients per year by precisely targeting tumors while sparing healthy tissue, especially for cancers near vital organs. The document calls for a workshop to develop a roadmap for establishing a Center of Excellence in India for proton therapy and advanced oncology technologies. The goal is to position India as a leader in cancer care through locally developed solutions.
Get the right cancer drug, at right TimeSubin Suresh
Mitra Biotech is a Boston and Bengaluru-based startup that is developing personalized cancer therapies. It focuses on testing drugs on recreated tumor microenvironments in the lab before human trials. This approach has higher success rates and lower toxicity than conventional trials. Mitra Biotech has raised over $27 million to develop these personalized therapies and diagnostics. Major challenges include high costs, ensuring data quality, and coordinating information between different treatment centers.
Radiation Therapy cost in Pune | Cancer Care PuneJagdish Shinde
Radiation therapy uses high-energy radiation to kill cancer cells and shrink tumors. It works by damaging the DNA of cancer cells, which grow and divide faster than normal cells. Radiation treatment can be delivered externally through machines or internally through radioactive implants placed near cancer cells. Researchers are studying ways to improve radiation therapy through radiosensitizers to make cancer cells more vulnerable and radioprotectors to protect healthy cells from radiation damage.
Radiation Treatment of Rectal and Colon Cancer :: July 2017 #CRCWebinarFight Colorectal Cancer
Michael Bassetti, MD, Ph.D. from the University of Wisconsin Carbone Cancer Center discusses all you need to know about radiation. Dr. Bassetti will talk about what radiation treatment is, how it’s used for rectal and colon cancer patients, how to prepare for treatment, how to manage side effects and more.
First of its kind in South India GE IQ PET/CT at MIOT HospitalsMIOT Hospitals
MIOT Hospitals provides nuclear medicine services including PET/CT scanning and targeted radionuclide therapy for cancers such as thyroid cancer, neuroendocrine tumors, and liver cancers. The department is equipped with a radionuclide therapy ward and offers therapies including radioiodine for thyroid cancer, radioiodinated MIBG for rare tumors, peptide receptor radionuclide therapy for neuroendocrine tumors, and radioembolization for liver cancers. MIOT aims to offer complete cancer care from diagnosis to rehabilitation all in one facility.
Radiation treatment dropouts-Pitfalls and solutions: A retrospective observa...Kanhu Charan
The study aimed to determine the factors influencing radiotherapy interruptions and provide solutions to decrease treatment dropouts. Of 1200 patients receiving radiation therapy, 100 (8.3%) experienced interruptions of over 5 days. The most common causes were radiation toxicity (20%), patient death (15%), financial issues (15%), and social issues (12%). After telephone counseling, treatment could restart in 25% of interrupted patients. To reduce interruptions, adequate counseling is needed before and during treatment, and financial support may help address the social determinants of treatment compliance.
Professor Maria Hawkins - UK SABR Service Development ExperiencesGenesisCareUK
- UK SABR service development experiences outlines the key requirements and considerations for establishing a stereotactic ablative radiotherapy (SABR) service, including specialized equipment, staff training, patient selection criteria, and quality assurance processes.
- SABR can be used to treat both primary tumors as well as metastatic cancers. It delivers a high radiation dose in few fractions compared to standard fractionation and has the potential for improved local control and quality of life.
- Establishing a SABR service requires a multidisciplinary team approach, specialized technology and imaging, rigorous patient selection, motion management strategies, and ongoing education and training of all clinical staff.
The document discusses cancer treatment facilities and incidence in Lao PDR. It notes that Lao PDR does not have cancer registries or adequate cancer treatment facilities. Patients must travel to neighboring countries for surgery, chemotherapy or radiotherapy. The most common cancers are estimated to be lung, stomach, liver and colorectal cancers in males and breast, cervical, stomach and colorectal cancers in females based on data from Vietnam. The document calls for increasing cancer awareness, training medical professionals, and establishing basic cancer treatment facilities in Lao PDR.
This document describes a new cancer therapy technique using tunable, monochromatic X-rays being developed by the company MXISystems. The technique shows promise in precisely targeting radiation therapy to cancer cells while sparing healthy tissue. However, commercializing the technology faces challenges including high capital costs, lack of supply chain for key components, and investor reluctance over perceived long-term risk. The document applies the framework of accelerated radical innovation to analyze MXISystems' innovation and determine how to accelerate its widespread clinical use by addressing challenges it faces in commercialization.
The document discusses proton therapy for treating oesophageal cancer and its potential benefits over other radiotherapy techniques. It summarizes that proton therapy may significantly reduce side effects from treatment and increase progression-free survival rates compared to IMRT. However, more research is still needed to address issues with dose distribution and motion management. It also stresses the importance of a patient-centered care approach to support patients physically and emotionally throughout treatment to improve quality of life given the poor survival rates for oesophageal cancer.
Explain the non safe or harm aspects of CT scan on the patient,, particularly after multiple CT scans done for one patient. mentioned essentially the risk of cancer in later life, which reach 1/2000.
Also, mentioned the organs, age group, and gender which affected more by CT radiation
Finally , stressing on eliminating CT scan as possible
Lung cancer is the most common cancer in males and second most common in females after breast cancer.
it is the third most commonly diagnosed and leading cause of cancer death in Pakistan, with an estimated 6,800 (4.6%) new cases and 6,013 (5.9%) deaths occurring in 2012
We have compared our data with the international statistics to see where do we stand.
In Pakistan, we do not have a valid central cancer registry at present which can provide a true picture of lung cancer. This calls for an urgent need to formulate a valid central cancer registry in the country in association with the local bodies.
7. Tom Lewis Getting it right for pathology presentationPHEScreening
This document summarizes a presentation on the Getting It Right First Time (GIRFT) program and its workstream focused on pathology. GIRFT aims to reduce unwarranted variation in clinical care through data collection, identifying best practices, and promoting changes. The pathology workstream is led by four clinical leads and aims to measure current variability in pathology services, create a vision for the future, and test changes. Key activities will include collecting data through questionnaires and site visits to understand variations and identify opportunities for improvement.
Radiation treatment machine capacity planning at cancer care ontario asliTopanArdiansyah1
Cancer Care Ontario (CCO) must allocate new linear accelerators to cancer treatment centers over five years to meet increasing demand for radiation therapy. Currently, 103 linear accelerators are operational across Ontario with 16 additional rooms available. CCO's directive is to fill these empty rooms before requesting funds to build new facilities. Jonathan Wang must develop an allocation strategy to distribute the 16 new linear accelerators approved for 2013-2017 in a way that best meets projected demand across the province.
Certis Oncology Solutions provides precision oncology solutions using patient-derived orthotopic xenograft (PDOX) mouse models to determine the best cancer therapies. Their three-step PDOX process implants patient tumor samples into mice to test multiple drug therapies simultaneously. This provides data to help oncologists individualize treatment for patients. Certis aims to improve outcomes by offering scientifically proven alternatives to standard of care therapies through their clinically relevant PDOX models.
Discover the future of cancer care at Apollo Proton Cancer Centre. Leading the way in medical oncology with advanced treatments for a brighter tomorrow.
This document discusses technology assessment, outcomes research, and economic analyses in healthcare. It provides background on rising healthcare costs in the US without clear improvements in health outcomes compared to other countries. The rationale for assessing new technologies and their impact is described. Key aspects of technology assessment are outlined, including technical efficacy, diagnostic accuracy, diagnostic impact, therapeutic impact, patient outcomes, and societal outcomes. Challenges with randomized controlled trials in assessing technologies are reviewed. The National Lung Screening Trial is presented as an example. Finally, computed tomography for appendicitis is analyzed as a hypothetical example of how modeling could be used to assess a technology when a randomized trial may not be feasible.
About the Ontario Institute for Cancer Researchjosephoicr
The Ontario Institute for Cancer Research’s focus on multi-disciplinary research teams, a collaborative approach and on moving discoveries into the clinic more quickly has advanced both discovery and translation.
This document summarizes an upcoming Cancer Diagnosis & Therapy Congress organized by MnM Conferences on September 3-4, 2015 in London. The two-day conference will bring over 150 experts from around the world to discuss advances in cancer diagnosis technologies and novel targeted cancer therapies. Key discussion topics will include interventional radiology techniques, immunotherapy, biomarkers, nanotechnology, biosensors, and functional genomics. Over 30 distinguished international speakers will present, including researchers from industry, academia, and hospitals. The conference aims to provide a platform for knowledge sharing between researchers, pharmaceutical companies, and doctors to collaborate and stay updated on the latest discoveries and technologies for cancer diagnosis and treatment.
Technology Assessment, Outcomes Research and Economic Analysesevadew1
This document discusses technology assessment, outcomes research, and economic analyses in healthcare. It provides background on rising healthcare costs in the US and outlines a hierarchy for assessing new medical technologies from technical efficacy to patient and societal outcomes. Randomized controlled trials are described as the gold standard but limitations are noted. Alternative study designs like modeling and assessing intermediate outcomes are proposed when RCTs are not feasible. The document uses CT for appendicitis as an example to work through initial steps in outcomes research. It also discusses limitations and alternative outcomes like assessing the therapeutic value of diagnostic tests.
The document discusses standard of care (SOC) costs in oncology clinical trials. It notes that SOC considerations can help avoid double payments and ensure fair market value, and that incorporating SOC into trial design and budgets can result in significant cost savings of up to 34%. SOC works well for oncology trials because national guidelines for cancer treatment (NCCN guidelines) are widely accepted and followed in the US and influence third-party payer reimbursement and protocol design.
MedicalResearch.com Medical Research News and Interviews September 26 2015Marie Benz
This study developed a new PET scan technique using a molecular probe tagged with copper-64 that can specifically detect blood clots anywhere in the body. Testing in animal models found the technique accurately detected 42 arterial and venous clots. It was also able to distinguish newer clots from older clots based on fibrin content and detect multiple clots simultaneously. The non-invasive whole body scan could help clinicians evaluate for clots in different areas with one procedure instead of multiple tests. Translating this technique has potential to improve patient care and management of conditions like pulmonary embolism and stroke.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
More Related Content
Similar to Investing Proton Therapy in China (part)
Radiation Therapy cost in Pune | Cancer Care PuneJagdish Shinde
Radiation therapy uses high-energy radiation to kill cancer cells and shrink tumors. It works by damaging the DNA of cancer cells, which grow and divide faster than normal cells. Radiation treatment can be delivered externally through machines or internally through radioactive implants placed near cancer cells. Researchers are studying ways to improve radiation therapy through radiosensitizers to make cancer cells more vulnerable and radioprotectors to protect healthy cells from radiation damage.
Radiation Treatment of Rectal and Colon Cancer :: July 2017 #CRCWebinarFight Colorectal Cancer
Michael Bassetti, MD, Ph.D. from the University of Wisconsin Carbone Cancer Center discusses all you need to know about radiation. Dr. Bassetti will talk about what radiation treatment is, how it’s used for rectal and colon cancer patients, how to prepare for treatment, how to manage side effects and more.
First of its kind in South India GE IQ PET/CT at MIOT HospitalsMIOT Hospitals
MIOT Hospitals provides nuclear medicine services including PET/CT scanning and targeted radionuclide therapy for cancers such as thyroid cancer, neuroendocrine tumors, and liver cancers. The department is equipped with a radionuclide therapy ward and offers therapies including radioiodine for thyroid cancer, radioiodinated MIBG for rare tumors, peptide receptor radionuclide therapy for neuroendocrine tumors, and radioembolization for liver cancers. MIOT aims to offer complete cancer care from diagnosis to rehabilitation all in one facility.
Radiation treatment dropouts-Pitfalls and solutions: A retrospective observa...Kanhu Charan
The study aimed to determine the factors influencing radiotherapy interruptions and provide solutions to decrease treatment dropouts. Of 1200 patients receiving radiation therapy, 100 (8.3%) experienced interruptions of over 5 days. The most common causes were radiation toxicity (20%), patient death (15%), financial issues (15%), and social issues (12%). After telephone counseling, treatment could restart in 25% of interrupted patients. To reduce interruptions, adequate counseling is needed before and during treatment, and financial support may help address the social determinants of treatment compliance.
Professor Maria Hawkins - UK SABR Service Development ExperiencesGenesisCareUK
- UK SABR service development experiences outlines the key requirements and considerations for establishing a stereotactic ablative radiotherapy (SABR) service, including specialized equipment, staff training, patient selection criteria, and quality assurance processes.
- SABR can be used to treat both primary tumors as well as metastatic cancers. It delivers a high radiation dose in few fractions compared to standard fractionation and has the potential for improved local control and quality of life.
- Establishing a SABR service requires a multidisciplinary team approach, specialized technology and imaging, rigorous patient selection, motion management strategies, and ongoing education and training of all clinical staff.
The document discusses cancer treatment facilities and incidence in Lao PDR. It notes that Lao PDR does not have cancer registries or adequate cancer treatment facilities. Patients must travel to neighboring countries for surgery, chemotherapy or radiotherapy. The most common cancers are estimated to be lung, stomach, liver and colorectal cancers in males and breast, cervical, stomach and colorectal cancers in females based on data from Vietnam. The document calls for increasing cancer awareness, training medical professionals, and establishing basic cancer treatment facilities in Lao PDR.
This document describes a new cancer therapy technique using tunable, monochromatic X-rays being developed by the company MXISystems. The technique shows promise in precisely targeting radiation therapy to cancer cells while sparing healthy tissue. However, commercializing the technology faces challenges including high capital costs, lack of supply chain for key components, and investor reluctance over perceived long-term risk. The document applies the framework of accelerated radical innovation to analyze MXISystems' innovation and determine how to accelerate its widespread clinical use by addressing challenges it faces in commercialization.
The document discusses proton therapy for treating oesophageal cancer and its potential benefits over other radiotherapy techniques. It summarizes that proton therapy may significantly reduce side effects from treatment and increase progression-free survival rates compared to IMRT. However, more research is still needed to address issues with dose distribution and motion management. It also stresses the importance of a patient-centered care approach to support patients physically and emotionally throughout treatment to improve quality of life given the poor survival rates for oesophageal cancer.
Explain the non safe or harm aspects of CT scan on the patient,, particularly after multiple CT scans done for one patient. mentioned essentially the risk of cancer in later life, which reach 1/2000.
Also, mentioned the organs, age group, and gender which affected more by CT radiation
Finally , stressing on eliminating CT scan as possible
Lung cancer is the most common cancer in males and second most common in females after breast cancer.
it is the third most commonly diagnosed and leading cause of cancer death in Pakistan, with an estimated 6,800 (4.6%) new cases and 6,013 (5.9%) deaths occurring in 2012
We have compared our data with the international statistics to see where do we stand.
In Pakistan, we do not have a valid central cancer registry at present which can provide a true picture of lung cancer. This calls for an urgent need to formulate a valid central cancer registry in the country in association with the local bodies.
7. Tom Lewis Getting it right for pathology presentationPHEScreening
This document summarizes a presentation on the Getting It Right First Time (GIRFT) program and its workstream focused on pathology. GIRFT aims to reduce unwarranted variation in clinical care through data collection, identifying best practices, and promoting changes. The pathology workstream is led by four clinical leads and aims to measure current variability in pathology services, create a vision for the future, and test changes. Key activities will include collecting data through questionnaires and site visits to understand variations and identify opportunities for improvement.
Radiation treatment machine capacity planning at cancer care ontario asliTopanArdiansyah1
Cancer Care Ontario (CCO) must allocate new linear accelerators to cancer treatment centers over five years to meet increasing demand for radiation therapy. Currently, 103 linear accelerators are operational across Ontario with 16 additional rooms available. CCO's directive is to fill these empty rooms before requesting funds to build new facilities. Jonathan Wang must develop an allocation strategy to distribute the 16 new linear accelerators approved for 2013-2017 in a way that best meets projected demand across the province.
Certis Oncology Solutions provides precision oncology solutions using patient-derived orthotopic xenograft (PDOX) mouse models to determine the best cancer therapies. Their three-step PDOX process implants patient tumor samples into mice to test multiple drug therapies simultaneously. This provides data to help oncologists individualize treatment for patients. Certis aims to improve outcomes by offering scientifically proven alternatives to standard of care therapies through their clinically relevant PDOX models.
Discover the future of cancer care at Apollo Proton Cancer Centre. Leading the way in medical oncology with advanced treatments for a brighter tomorrow.
This document discusses technology assessment, outcomes research, and economic analyses in healthcare. It provides background on rising healthcare costs in the US without clear improvements in health outcomes compared to other countries. The rationale for assessing new technologies and their impact is described. Key aspects of technology assessment are outlined, including technical efficacy, diagnostic accuracy, diagnostic impact, therapeutic impact, patient outcomes, and societal outcomes. Challenges with randomized controlled trials in assessing technologies are reviewed. The National Lung Screening Trial is presented as an example. Finally, computed tomography for appendicitis is analyzed as a hypothetical example of how modeling could be used to assess a technology when a randomized trial may not be feasible.
About the Ontario Institute for Cancer Researchjosephoicr
The Ontario Institute for Cancer Research’s focus on multi-disciplinary research teams, a collaborative approach and on moving discoveries into the clinic more quickly has advanced both discovery and translation.
This document summarizes an upcoming Cancer Diagnosis & Therapy Congress organized by MnM Conferences on September 3-4, 2015 in London. The two-day conference will bring over 150 experts from around the world to discuss advances in cancer diagnosis technologies and novel targeted cancer therapies. Key discussion topics will include interventional radiology techniques, immunotherapy, biomarkers, nanotechnology, biosensors, and functional genomics. Over 30 distinguished international speakers will present, including researchers from industry, academia, and hospitals. The conference aims to provide a platform for knowledge sharing between researchers, pharmaceutical companies, and doctors to collaborate and stay updated on the latest discoveries and technologies for cancer diagnosis and treatment.
Technology Assessment, Outcomes Research and Economic Analysesevadew1
This document discusses technology assessment, outcomes research, and economic analyses in healthcare. It provides background on rising healthcare costs in the US and outlines a hierarchy for assessing new medical technologies from technical efficacy to patient and societal outcomes. Randomized controlled trials are described as the gold standard but limitations are noted. Alternative study designs like modeling and assessing intermediate outcomes are proposed when RCTs are not feasible. The document uses CT for appendicitis as an example to work through initial steps in outcomes research. It also discusses limitations and alternative outcomes like assessing the therapeutic value of diagnostic tests.
The document discusses standard of care (SOC) costs in oncology clinical trials. It notes that SOC considerations can help avoid double payments and ensure fair market value, and that incorporating SOC into trial design and budgets can result in significant cost savings of up to 34%. SOC works well for oncology trials because national guidelines for cancer treatment (NCCN guidelines) are widely accepted and followed in the US and influence third-party payer reimbursement and protocol design.
MedicalResearch.com Medical Research News and Interviews September 26 2015Marie Benz
This study developed a new PET scan technique using a molecular probe tagged with copper-64 that can specifically detect blood clots anywhere in the body. Testing in animal models found the technique accurately detected 42 arterial and venous clots. It was also able to distinguish newer clots from older clots based on fibrin content and detect multiple clots simultaneously. The non-invasive whole body scan could help clinicians evaluate for clots in different areas with one procedure instead of multiple tests. Translating this technique has potential to improve patient care and management of conditions like pulmonary embolism and stroke.
Similar to Investing Proton Therapy in China (part) (20)
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Role of Mukta Pishti in the Management of Hyperthyroidism
Investing Proton Therapy in China (part)
1. Building Proton Therapy In
China: A Due Diligence Report
Yanfeng Alex Wang
yanfeng12@hotmail.com
May 28, 2016
2. • How To Build A Proton Therapy Center
• Technology
• What is proton therapy?
• Proton therapy emerges as the latest option to improve
radiotherapy delivery
• Proton therapy overcomes key barriers and becomes commercially
feasible
• Proton therapy centers in U.S.: 23 in operation, 13 in development
or under construction
• Market
• Rapid growth of cancer cases demands increased capacity of
treatment
• China grows fastest in cancer cases
• Proton therapy will cover nine of top ten cancers in China
• Exponential growth of demand on proton therapy
• Projected market size of China: 150 proton therapy centers
• China has two centers in operation
• Finance
• Investment in proton therapy: revenue
• Investment in proton therapy: investment IRR
• Investment in proton therapy: sensitivity test
• Pricing: how much would people pay for proton therapy?
• Price vs. patient throughput: how do they affect investment return?
• How to improve patient throughput?
• Operating margin: a key consideration during negotiation
• Five or one: large center or single unit?
• Human & Organization
• Proton therapy investment: stakeholders analysis
• Proton therapy investment: key hospitals for collaboration --- cancer
specialty hospitals
• Proton therapy investment: key hospitals for collaboration --- top 50
general hospitals
• Case study: a tier-3 city’s ambition to own proton therapy
• Project & Planning
• Proton therapy investment: structure of a possible deal (example)
• Access potential market: how do overseas investors engage in
business development?
• Proton therapy investment: project by phase, risk & solution
• Readiness of proton therapy project
• Appendix: top 50 general hospitals in China
Outline
Outline
3. Outline
How To Build A Proton Therapy Center
Real Estate
Healthcare
Technology
Investment
Choice of location, approval of land, construction planning and design
Hospital operation, medical staff training, patient referral
Vendor support, equipment installation, image & IT support
Funding resources, investment modeling, transaction/tax advisory
Building proton therapy center requires expertise of multiple dimensions. All those expertise need to be
carefully orchestrated for successful outcomes. In order to build proton therapy center in China, synergy of
resources from both China and United States can facilitate success of investment.
Culture Negotiation, relationship development, risk management
4. • A frontier radiology technology to treat cancer
• It uses proton beam to kill tumor cells
• It has advantage over conventional radiation, with little damage to
surrounding healthy tissue
• For 30% of all cancer cases, proton therapy has significant advantage
over conventional radiation. For the remaining 70% cases, conventional
radiation works as effectively as proton therapy for now
• Proton therapy was invented in late 1980s. There are 23 proton therapy
centers in U.S. and more to come (refer to “technology: PT centers in
U.S.”)
Technology
What Is Proton Therapy?
• Conventional proton therapy facility needs large construction area of 100,000 square feet. A latest compact version including a single
treatment room uses much less construction area of 2,800 square feet
• Proton therapy center operates like a nuclear plant. Its equipment accelerates proton beam to 2/3 of light speed for treatment. The center
is always built in ground floor and underground like a nuclear bunker, with wall fortification required to block radiation
• Navigated by magnet, photon beam can be guided into up to 5 treatment rooms. Which means the maximum capacity of a center is five
treatment rooms
• Patient will lie still on a treatment bed, while the equipment can be rotated 360 degree in order to orient proton beams to tumor foci. Its
precision can reach 0.5 mm (tumor won’t be totally still because it moves along with breathing and heart beating)
• Among 5 treatment rooms, a popular setup includes 4 rotational and 1 fixed beam room. It reflects breakdown of treatment types,
because some patients won’t need rotational beam
5. Technology
Proton Therapy Emerges As The Latest Option
To Improve Radiotherapy Delivery
HDRT: high dose radiotherapy
Due to advantage of its
technology (proton vs.
photon), proton therapy
represents the latest trend
of radiotherapy(RT) by
delivering high dose
radiation precisely, to
achieve faster, better, and
safer therapy
6. Since the technology was invented nearly three decades ago, how come it hasn’t
been popular until recently? There are a few key barriers:
• Debate about advantage of proton therapy over conventional radiotherapy. It’s not
until recent two years when accumulated data show convincing outcomes
• Proton therapy can focus on tumor without radiating surrounding tissue. The
figure on the right compares radiated areas by proton therapy and
conventional radiotherapy in a heat map. Proton therapy can focus on tumor
alone, while conventional radiotherapy affects unintended nearby organs
such as heart
• 30% of all cancer cases can significantly benefit from proton therapy. Doctors
can advise patient whether his/her case should be subject to proton therapy
or conventional radiotherapy
• Scope of investment. Construction of a proton therapy center used to take four
years or longer. Total investment can be $200 million for a 5-treatment room center.
Investors hesitated on large amount of money, long time line, and uncertain buy-in
from patients and providers. Those hurdles can be overcome, which results in
acceleration of investment to new proton therapy centers
• Reimbursement. Medical insurance doesn’t always have a complete coverage of
proton therapy. For example, if conventional radiotherapy receives $2,000
reimbursement, while proton therapy costs $5,000, medical insurance will only
cover $2,000 for proton therapy. The remaining $3,000 will come from patients or
providers. Large patient volume is the key to drive down operating cost. Now
proton therapy is almost on par with conventional radiotherapy if managed properly
Proton Therapy Overcomes Key Barriers
And Becomes Commercially Feasible
Technology
Proton therapy can be less expensive
than surgery and chemotherapy
7. Technology
PT Centers In United States: 23 In Operation,
13 In Development Or Under Construction
Robert Wood Johnson
Northwestern Medicine
U.Florida Health (UFPTI)
U.Florida Health Cancer
Center Orlando
S Lee Kling, St. Louis
TPTC Provision Healthcare
Ackerman Cancer
Center
Procure, Oklahoma City
Procure, Princeton
Willis Knighton
Cancer Center
Hampton Univ.
Loma Linda (LLUMC)
Maryland MPTC
Mayo Clinic Arizona
Mayo Clinic Rochester
MD Anderson
U. Penn
Scripps, San Diego
SCCA Seattle
Texas Center for PT (Baylor)
Mass General (MGH)
CDH
St. Jude Children’s
Oklahoma Univ.
University Hospital
Georgetown Univ.
Georgia PT (Emory)
Cincinnati Children’s
Beaumont Health
Baptist Health South FL
McLaren Health, Flint New York PT Center
Dallas PT Center (UT Southwestern)
UCSF Ocular
Los Angeles PT Center
Scott Hamilton PT Center
Johns Hopkins Sibly
Center in operation
Center in development
or under construction
8. Market
Rapid Growth Of Cancer Cases Demands More
Capacity Of Treatment
Cancer ranks No.2 as cause of
death. Aging population and
improved life expectancy result in
rapid growth of cancer cases. By
2030, new cancer cases will be 80%
higher than current level, reaching
25 million per year
9. • China has 3 to 3.5 million of new cancer cases per year.
Because of its fast aging population (300 million over 65
years old by 2030), by 2030 China will have 5.6 million
new cancer cases a year
• The top three cancer types are lung, stomach, and liver
cancer, which correlates with sustaining social-
environmental health factors such as smoking, air
pollution, diet, and high incidence of hepatitis
Market
China Grows Fastest In Cancer Cases
• Different cancer type has its geographical distribution.
For example, liver cancer incidence is high in southern
coastal provinces where people consume a lot
seafood. Geographical distribution of cancer types will
become a factor when investors choose sites of new
proton therapy centers
• Geographical difference of wealth can implicate
affordability of premium treatment. According to GDP
per capita, coastal provinces and some inland regions
are more likely to pursue premium health technology
than provinces in Midwest
Geographical Distribution Of
Cancer Types
Blue: stomach cancer
Yellow: esophagus cancer
Green: liver cancer GDP Per Capita By Province
10. Proton therapy has been used to treat 9 out of top 10 most prevalent cancers in China. Liver cancer is the only
exception. Besides cancer, proton therapy has potential to treat other medical conditions.
Market
Proton Therapy Will Cover Nine Of
Top Ten Cancers In China
11. Market
Exponential Growth Of Demand On Proton
Therapy
A conservative estimate projects 4X growth of number of treatment rooms in 10 years. Purchase of proton therapy equipment
has accelerated since last year. Some PT vendors have reported backlog of orders.
12. • China has 3.5 million of new diagnosis cancer cases per year. This number will increase to 5.6
million by 2030 due to aging population, equivalent to 3% annual growth
• Between 20% to 30% (average 25%) of cancer cases should be treated by proton therapy: 3.5
million X 25% = 875K cases per year
• Assuming 10% of all patients can afford and would pay for proton therapy: 875K X 10%
= 87.5K cases per year
• Therefore, market size of proton therapy in China is 87.5 thousand cases per year
• If there are 87.5 thousand cases per year, how many proton therapy centers does China
need?
• China needs to build 150 proton therapy centers (or 350 treatment rooms total) to fulfill
demand (refer to finance, table of revenue projection), with 3% annual growth
• Assuming China will take 5 years to build 150 centers (30 per year), and every center costs
$100 million, the nation needs to invest $3 billion per year in proton therapy centers
• Reality check: is China willing to spend $3 billion per year to improve its cancer treatment?
• In 2013, 5.4% GDP or $511.3 billion was spent on healthcare in China. The nation could pay
$6 billion by itself, but would be more willing to attract non-government investment for such
projects
Market
Projected Market Size Of China: 150 Proton
Therapy Centers
3.5 million new
patients per year
Market size: 87.5
thousand patients will
need and can pay for
proton therapy
Market demand:
around 150 proton
therapy centers
13. In operation
• Wanjie Center, Zibo (Shandong Prov.) has been in operation since 2004. Because
of management and other issues, Wanjie has not fully realized its marketing
potential
• Shanghai Proton and Heavy Ion Center uses technology provided by Siemens, and
is co-managed with Fudan University. It opened in 2014. Because carbon cation
instead of proton is used, strictly speaking it does not belong to proton therapy. The
center is for research, not for commercial purpose
In development or under construction
• Beijing 301 Military Hospital is planning a proton therapy facility (5 treatment
rooms). The center may be designated for privileged citizens due to its military
background. The facility will locate in Zhuozhou (Hebei Prov.), 30 miles southwest
to Beijing. Zhuozhou is chosen because there’s no land in downtown Beijing. The
center will use IBA technology
• Tianjin Cancer Hospital signed a deal, pending for approval. It will use IBA
• Shenyang (Liaoning Prov.) signed a deal, pending for approval. It will use Varian
• Shiyan (Hubei Prov.). The hospital will expand to 3,000 beds, and become a cancer
hospital. It will use Varian
• Guangzhou is planning a 3-room proton therapy center, and expected to open in
late 2018. It will use IBA
Market
China Has Two Centers In Operation
Major vendors:
• Varian (U.S.)
• IBA (Belgium)
• Hitachi (Japan)
Center in operation
Center in development
or under construction
Shenyang
Zhuozhou, Hebei
Tianjin
Weifang, Shandong
Shanghai
Shiyan, Hubei
Guangzhou
Editor's Notes
Cancer Types
Proton therapy is used for a variety of cancer types, and at Penn Medicine we are constantly working to expand the list of conditions treated with proton therapy.
Below are some of the cancers treated with proton therapy:
Brain cancer and spinal tumors
Breast cancer
Gastrointestinal (GI) cancer (colon, esophageal, kidney, pancreatic)
Gynecologic (cervical cancer)
Head and neck cancer
Lung cancer
Lymphoma
Mesothelioma
Pediatric cancer, in conjunction with the Children's Hospital of Philadelphia
Prostate cancer
Sarcomas
http://www.pennprotontherapy.org/cancers-we-treat/
Cancer Types
Proton therapy is used for a variety of cancer types, and at Penn Medicine we are constantly working to expand the list of conditions treated with proton therapy.
Below are some of the cancers treated with proton therapy:
Brain cancer and spinal tumors
Breast cancer
Gastrointestinal (GI) cancer (colon, esophageal, kidney, pancreatic)
Gynecologic (cervical cancer)
Head and neck cancer
Lung cancer
Lymphoma
Mesothelioma
Pediatric cancer, in conjunction with the Children's Hospital of Philadelphia
Prostate cancer
Sarcomas
http://www.pennprotontherapy.org/cancers-we-treat/
Estimated health care expenditure: $511.3 billion in 2013Health care as a share of GDP: 5.4 percent in 20131
http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-china.pdf